GlassScriptPhysician profile
Elnaz Kasiri
NPI 1831657667
$6,050.29
in general payments reported to CMS, 2019-2025
30 companies · $3,896 in 2025
The $3,896 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2024: $2,021 · 2025: $3,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,916.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $889.24 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $858.21 | 2024-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $761.46 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Novo Nordisk INC | $608.10 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $484.24 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.94 | 2022-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $249.32 | 2024-2025 | Yorvipath |
| Lilly USA, LLC | $243.60 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $207.38 | 2024-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $155.18 | 2024 | |
| Tandem Diabetes Care, INC. | $145.30 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $142.95 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $119.81 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $119.14 | 2025 | |
| Sequel Med Tech, LLC | $92.47 | 2025 | Twiist |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $92.42 | 2024-2025 | Omnipod |
| Kyowa Kirin, INC. | $77.57 | 2024 | Crysvita |
| Madrigal Pharmaceuticals | $61.71 | 2025 | Rezdiffra |
| Radius Health, INC. | $51.06 | 2024-2025 | Tymlos |
| Glaxosmithkline, LLC. | $47.67 | 2025 | Arexvy, Shingrix |
| Beta Bionics, INC. | $43.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $42.82 | 2025 | |
| Medtronic, INC. | $42.45 | 2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $41.16 | 2024 | Signifor Lar, Isturisa |
| Ascensia Diabetes Care US INC. | $37.84 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.95 | 2024 | |
| Cequr Corporation | $32.21 | 2024 | Cequr Simplicity |
| Almatica Pharma LLC | $29.73 | 2025 | Teriparatide |
| Astrazeneca Pharmaceuticals LP | $16.92 | 2025 | Farxiga |
| Ibsa Pharma INC. | $14.53 | 2024 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elnaz Kasiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.